Phenylacetic acids and the structurally related non-steroidal anti-inflammatory drug diclofenac bind to specific gamma-hydroxybutyric acid sites in rat brain

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Phenylacetic acids and the structurally related non-steroidal anti-inflammatory drug diclofenac bind to specific gamma-hydroxybutyric acid sites in rat brain. / Wellendorph, Petrine; Høg, Signe; Skonberg, Christian; Bräuner-Osborne, Hans.

In: Fundamental and Clinical Pharmacology, Vol. 23, No. 2, 2009, p. 207-213.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Wellendorph, P, Høg, S, Skonberg, C & Bräuner-Osborne, H 2009, 'Phenylacetic acids and the structurally related non-steroidal anti-inflammatory drug diclofenac bind to specific gamma-hydroxybutyric acid sites in rat brain', Fundamental and Clinical Pharmacology, vol. 23, no. 2, pp. 207-213. https://doi.org/10.1111/j.1472-8206.2008.00664.x

APA

Wellendorph, P., Høg, S., Skonberg, C., & Bräuner-Osborne, H. (2009). Phenylacetic acids and the structurally related non-steroidal anti-inflammatory drug diclofenac bind to specific gamma-hydroxybutyric acid sites in rat brain. Fundamental and Clinical Pharmacology, 23(2), 207-213. https://doi.org/10.1111/j.1472-8206.2008.00664.x

Vancouver

Wellendorph P, Høg S, Skonberg C, Bräuner-Osborne H. Phenylacetic acids and the structurally related non-steroidal anti-inflammatory drug diclofenac bind to specific gamma-hydroxybutyric acid sites in rat brain. Fundamental and Clinical Pharmacology. 2009;23(2):207-213. https://doi.org/10.1111/j.1472-8206.2008.00664.x

Author

Wellendorph, Petrine ; Høg, Signe ; Skonberg, Christian ; Bräuner-Osborne, Hans. / Phenylacetic acids and the structurally related non-steroidal anti-inflammatory drug diclofenac bind to specific gamma-hydroxybutyric acid sites in rat brain. In: Fundamental and Clinical Pharmacology. 2009 ; Vol. 23, No. 2. pp. 207-213.

Bibtex

@article{d584730030b311de87b8000ea68e967b,
title = "Phenylacetic acids and the structurally related non-steroidal anti-inflammatory drug diclofenac bind to specific gamma-hydroxybutyric acid sites in rat brain",
abstract = "Gamma-Hydroxybutyric acid (GHB) is a proposed neurotransmitter or neuromodulator with a yet unresolved mechanism of action. GHB binds to both specific high-affinity GHB binding sites and to gamma-aminobutyric acid subtype B (GABA(B)) receptors in the brain. To separate specific GHB effects from GABA(B) receptor effects, it is imperative to develop GHB selective and potent compounds. We generated the compound, 4-(biphen-4-yl)-4-hydroxybutyric acid, which is the 4-hydroxyl analogue of the non-steroidal anti-inflammatory drug (NSAID) fenbufen (referred to as gamma-hydroxyfenbufen). When measured in a rat brain homogenate [(3)H]NCS-382 binding assay, gamma-hydroxyfenbufen inhibited [(3)H]NCS-382 binding with a 10-fold higher affinity than GHB (K(i) 0.44 microM), thus establishing it as a novel lead structure. The active metabolite of fenbufen, 4-biphenylacetic acid inhibited [(3)H]NCS-382 binding with a twofold higher affinity than GHB. Measuring the affinities of structurally related NSAIDs for the [(3)H]NCS-382 site identified diclofenac, a clinically relevant NSAID (Voltaren, Diclon) of the phenylacetic acid (PAA) type, as a GHB ligand (K(i) value of 5.1 microM). Other non-NSAID PAAs also exhibited affinities similar to GHB. Our data raise the interesting possibility that the widely used over-the-counter drug compound, diclofenac, might affect GHB binding at relevant clinical dosages. Furthermore, the identification of PAAs as GHB ligands supplies new information about the structural preferences of the GHB ligand-binding site.",
keywords = "Animals, Anti-Inflammatory Agents, Non-Steroidal, Binding Sites, Brain, Diclofenac, Hydroxybutyrates, Ligands, Male, Phenylacetates, Protein Binding, Rats, Rats, Sprague-Dawley, Receptors, Cell Surface, Structure-Activity Relationship",
author = "Petrine Wellendorph and Signe H{\o}g and Christian Skonberg and Hans Br{\"a}uner-Osborne",
note = "Keywords: binding; diclofenac; non-steroidal anti-inflammatory drug; phenylacetic acid; gamma-hydroxybutyric acid",
year = "2009",
doi = "10.1111/j.1472-8206.2008.00664.x",
language = "English",
volume = "23",
pages = "207--213",
journal = "Fundamental and Clinical Pharmacology",
issn = "0767-3981",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Phenylacetic acids and the structurally related non-steroidal anti-inflammatory drug diclofenac bind to specific gamma-hydroxybutyric acid sites in rat brain

AU - Wellendorph, Petrine

AU - Høg, Signe

AU - Skonberg, Christian

AU - Bräuner-Osborne, Hans

N1 - Keywords: binding; diclofenac; non-steroidal anti-inflammatory drug; phenylacetic acid; gamma-hydroxybutyric acid

PY - 2009

Y1 - 2009

N2 - Gamma-Hydroxybutyric acid (GHB) is a proposed neurotransmitter or neuromodulator with a yet unresolved mechanism of action. GHB binds to both specific high-affinity GHB binding sites and to gamma-aminobutyric acid subtype B (GABA(B)) receptors in the brain. To separate specific GHB effects from GABA(B) receptor effects, it is imperative to develop GHB selective and potent compounds. We generated the compound, 4-(biphen-4-yl)-4-hydroxybutyric acid, which is the 4-hydroxyl analogue of the non-steroidal anti-inflammatory drug (NSAID) fenbufen (referred to as gamma-hydroxyfenbufen). When measured in a rat brain homogenate [(3)H]NCS-382 binding assay, gamma-hydroxyfenbufen inhibited [(3)H]NCS-382 binding with a 10-fold higher affinity than GHB (K(i) 0.44 microM), thus establishing it as a novel lead structure. The active metabolite of fenbufen, 4-biphenylacetic acid inhibited [(3)H]NCS-382 binding with a twofold higher affinity than GHB. Measuring the affinities of structurally related NSAIDs for the [(3)H]NCS-382 site identified diclofenac, a clinically relevant NSAID (Voltaren, Diclon) of the phenylacetic acid (PAA) type, as a GHB ligand (K(i) value of 5.1 microM). Other non-NSAID PAAs also exhibited affinities similar to GHB. Our data raise the interesting possibility that the widely used over-the-counter drug compound, diclofenac, might affect GHB binding at relevant clinical dosages. Furthermore, the identification of PAAs as GHB ligands supplies new information about the structural preferences of the GHB ligand-binding site.

AB - Gamma-Hydroxybutyric acid (GHB) is a proposed neurotransmitter or neuromodulator with a yet unresolved mechanism of action. GHB binds to both specific high-affinity GHB binding sites and to gamma-aminobutyric acid subtype B (GABA(B)) receptors in the brain. To separate specific GHB effects from GABA(B) receptor effects, it is imperative to develop GHB selective and potent compounds. We generated the compound, 4-(biphen-4-yl)-4-hydroxybutyric acid, which is the 4-hydroxyl analogue of the non-steroidal anti-inflammatory drug (NSAID) fenbufen (referred to as gamma-hydroxyfenbufen). When measured in a rat brain homogenate [(3)H]NCS-382 binding assay, gamma-hydroxyfenbufen inhibited [(3)H]NCS-382 binding with a 10-fold higher affinity than GHB (K(i) 0.44 microM), thus establishing it as a novel lead structure. The active metabolite of fenbufen, 4-biphenylacetic acid inhibited [(3)H]NCS-382 binding with a twofold higher affinity than GHB. Measuring the affinities of structurally related NSAIDs for the [(3)H]NCS-382 site identified diclofenac, a clinically relevant NSAID (Voltaren, Diclon) of the phenylacetic acid (PAA) type, as a GHB ligand (K(i) value of 5.1 microM). Other non-NSAID PAAs also exhibited affinities similar to GHB. Our data raise the interesting possibility that the widely used over-the-counter drug compound, diclofenac, might affect GHB binding at relevant clinical dosages. Furthermore, the identification of PAAs as GHB ligands supplies new information about the structural preferences of the GHB ligand-binding site.

KW - Animals

KW - Anti-Inflammatory Agents, Non-Steroidal

KW - Binding Sites

KW - Brain

KW - Diclofenac

KW - Hydroxybutyrates

KW - Ligands

KW - Male

KW - Phenylacetates

KW - Protein Binding

KW - Rats

KW - Rats, Sprague-Dawley

KW - Receptors, Cell Surface

KW - Structure-Activity Relationship

U2 - 10.1111/j.1472-8206.2008.00664.x

DO - 10.1111/j.1472-8206.2008.00664.x

M3 - Journal article

C2 - 19645815

VL - 23

SP - 207

EP - 213

JO - Fundamental and Clinical Pharmacology

JF - Fundamental and Clinical Pharmacology

SN - 0767-3981

IS - 2

ER -

ID: 12002862